Gastroenterology
Volume 130, Issue 3 , Pages 935-939, March 2006

American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease

  • Gary R. Lichtenstein

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Chair, Clinical Practice and Economics Committee, AGA National Office, c/o Membership Department, 4930 Del Ray Avenue, Bethesda, Maryland 20814. fax: (301) 654-5920.

Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania

Mount Sinai School of Medicine Mount Sinai Medical Center New York, New York

University of Chicago Hospitals University of Chicago School of MedicineChicago, Illinois

Mayo Clinic College of MedicineMayo Clinic Rochester, Minnesota

No abstract is available. To read the body of this article, please view the Full Text online.

 

 Dr. Lichtenstein is a consultant for Abbott Corporation, Astra-Zeneca, Inc., Axcan Corporation, Berlex, Centocor, Inc., Elan, Genetics Institute, Human Genome Sciences, Inkine, Inc., Intesco Corporation, ISIS Corporation, Millenium Pharmaceuticals, Otsuka Corporation, Proctor and Gamble, Prometheus Laboratories, Inc., Protein Design Labs, Protomed Scientific, Salix Pharmaceuticals, Schering-Plough Corporation, Serono, Shire Pharmaceuticals, Smith Kline Beecham Corporation, Solvay Pharmaceuticals, Synta Pharmaceuticals, UCB, and Wyeth.

 Dr. Tremaine is a consultant for Procter and Gamble, NPS Pharma, and Solvay Pharma.

 Dr. Abreu is a consultant for Procter and Gamble, Abbott, UCB, Prometheus, and Salix.

 Dr. Cohen is a consultant for Salix, Centocor, Abbott, Elan, Isis, Kenwood, McNeil, Pfizer, Protein Design Labs, Astra-Zeneca, Axcan-Scandipharm, Procter and Gamble, Salix, Solvay, and Shire.

 This document presents the official recommendations of the American Gastroenterological Association (AGA) on “Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease.” It was approved by the Clinical Practice and Economics Committee on November 22, 2005, and by the AGA Governing Board on January 12, 2006.

 The Medical Position Statements (MPS) developed under the aegis of the American Gastroenterological Association (AGA) and its Clinical Practice and Economics Committee (CPEC) were approved by the AGA Governing Board. The data used to formulate these recommendations are derived from the data available at the time of their creation and may be supplemented and updated as new information is assimilated. These recommendations are intended for adult patients, with the intent of suggesting preferred approaches to specific medical issues or problems. They are based upon the interpretation and assimilation of scientifically valid research, derived from a comprehensive review of published literature. Ideally, the intent is to provide evidence based upon prospective, randomized placebo-controlled trials; however, when this is not possible, the use of experts' consensus may occur. The recommendations are intended to apply to health care providers of all specialties. It is important to stress that these recommendations should not be construed as a standard of care. The AGA stresses that the final decision regarding the care of the patient should be made by the physician with a focus on all aspects of the patient's current medical situation.

PII: S0016-5085(06)00073-4

doi:10.1053/j.gastro.2006.01.047

Gastroenterology
Volume 130, Issue 3 , Pages 935-939, March 2006

Article Tools